We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Medical Devices » Labeling for Prescription Drugs, Biologics and Combination Products – Webinar Recording/ Transcript

Other Options

USB Audio Recording/Transcript - Oct. 29, 2019

$287.00

USB Audio Recording/Transcript - Oct. 29, 2019

$258.00

USB Audio Recording/Transcript - Oct. 29, 2019

$244.00

USB Audio Recording/Transcript - Oct. 29, 2019

$230.00

USB Audio Recording/Transcript - Oct. 29, 2019

$215.00
webinar recording

Labeling for Prescription Drugs, Biologics and Combination Products – Webinar Recording/ Transcript

$287.00
Medical Devices

Product Details

Labeling for Prescription Drugs, Biologics and Combination Products: Complying with FDA’s Most Recent IFU Guidance

The FDA guidance on Instructions for Use (IFU) issued in July 2019 aims to make labeling of prescription drugs, biologics and combination products clearer and more helpful to patients. But this could have implications for your business’ NDAs and BLAs.

If you’re unsure how to proceed, you’re not alone. In this presentation, Alan G. Minsk, Esq. — a partner and leader of the Food & Drug Practice Team of Arnall Golden Gregory LLP — will clarify the new guidance and explain how to comply with it, focusing on the issues you must consider as you implement changes to your IFUs.

Presentation Takeaways:

  • Why FDA issued the draft guidance and its importance to regulatory, quality and compliance specialists, including the content and format concerns of FDA in general and details necessary for safe and effective use
  • What kind of language IFUs should be written in to be patient friendly
  • What the guidance recommends in terms of voice, commands and sentences
  • Examples of sample labeling that covers all elements of an IFU from dosage and usage to storage and disposal
  • What kinds of recommendations FDA makes in terms of design and layout, such as the use of easy-to-read fonts, sequential numbering and white space
  • Some practical considerations on patient labeling, from a business perspective

If you are at all unclear how to implement this guidance and change your IFUs to include what FDA considers to be “clear, concise information that is easily understood,” you listen to this presentation. Your NDAs and BLAs depend on it.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing